CD274 and non-small cell lung carcinoma: Although several studies have reported on the relationship between the GPS and ICI treatment efficacy in NSCLC for different lines of treatment, various ICIs, and various levels of PD‐L1 expression,14, 15 no studies have evaluated the relationship between the GPS and the efficacy of first‐line pembrolizumab monotherapy for NSCLC in patients with high PD‐L1 expression.